Last update 20 Mar 2025

Interferon beta-1b biosimilar(AMEGA Biotech)

Overview

Basic Info

Drug Type
Interferons, Biosimilar
Synonyms
Actoferon, Interferon beta-1b biosimilar r(AMEGA Biotech)
Target
IFNAR
Action
agonists, modulators
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Therapeutic Areas
Immune System DiseasesNervous System DiseasesOther Diseases
Active Indication
Multiple Sclerosis
Inactive Indication-
Originator Organization
AMEGA BiotechAMEGA Biotech
Active Organization
AMEGA BiotechAMEGA Biotech
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Iran (01 Jan 2014),
Multiple Sclerosis
Regulation-
Login to view timeline

Structure/Sequence

Related

1
Clinical Trials associated with Interferon beta-1b biosimilar(AMEGA Biotech)
IRCT2013030512398N2
/ CompletedPhase 3
A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)
100 Clinical Results associated with Interferon beta-1b biosimilar(AMEGA Biotech)
Login to view more data
100 Translational Medicine associated with Interferon beta-1b biosimilar(AMEGA Biotech)
Login to view more data
100 Patents (Medical) associated with Interferon beta-1b biosimilar(AMEGA Biotech)
Login to view more data
100 Deals associated with Interferon beta-1b biosimilar(AMEGA Biotech)
Login to view more data

External Link

KEGGWikiATCDrug Bank
--
L03AB08
DB00068

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
Iran
AMEGA BiotechAMEGA Biotech
01 Jan 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ECTRIMS2022
Not Applicable
Multiple Sclerosis, Relapsing-Remitting
140
lrzvtaocth(uzuatemovs) = vglxulaxay hcjasepwva (jddznqghfx )
View more
Positive
12 Oct 2022
lrzvtaocth(uzuatemovs) = pdfcffmyyk hcjasepwva (jddznqghfx )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free